Am J Otolaryngol:鼻中隔成形术后,过敏性鼻炎对鼻塞治疗结果的影响

2018-03-27 AlexYang MedSci原创

为了评估是否过敏性鼻炎(AR)的诊断会对开放式鼻中隔成形术(OSR)的外科手术治疗产生影响以及调查是否OSR是否能够对过敏性鼻炎患者或者不患有过敏性鼻炎的患者提供同样水平的生活质量的提高。研究人员在2008年到2015年进行了相关的回顾性研究,研究包括了646名经历了开放式鼻中隔成形术的病人。研究人员对满足入选条件的307名患者利用鼻塞症状评估(NOSE)模块进行了术前和术后生活质量(QoL)的测

为了评估是否过敏性鼻炎(AR)的诊断会对开放式鼻中隔成形术(OSR)的外科手术治疗产生影响以及调查是否OSR是否能够对过敏性鼻炎患者或者不患有过敏性鼻炎的患者提供同样水平的生活质量的提高。

研究人员在2008年到2015年进行了相关的回顾性研究,研究包括了646名经历了开放式鼻中隔成形术的病人。研究人员对满足入选条件的307名患者利用鼻塞症状评估(NOSE)模块进行了术前和术后生活质量(QoL)的测量,并且根据是否患有过敏性鼻炎分成2组进行相关比较。研究发现,非AR组包括213名患者,AR组包括94名患者。OSR之后,2个小组的患者的比通道阻塞得到了显著的改善。术前NOSE得分平均值在非AR和AR两个小组之间相似(69.9 vs 73.4,p=0.087)。另外,在第30天NOSE得分在非AR和AR两个小组之间的平均提高分别为48.6 vs 45.9 (p=0.41);在第90天分别为 48.1 vs 51.5 (p=0.402)。

最后,研究人员指出,根据NOSE得分,患有或者不患有过敏性鼻炎经历了相似的OSR治疗结果。开放式鼻中隔成形术在鼻通道阻塞中的作用是多方面的,并且也许抵消了过敏性鼻炎的作用。

原始出处:

Sokoya M, Gonzalez JR, Winkler AA et al. Effect of allergic rhinitis on nasal obstruction outcomes after functional open septorhinoplasty. Am J Otolaryngol. 5 Mar 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046948, encodeId=969920469488d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 21 18:43:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004693, encodeId=2ee0200469350, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Mon Oct 15 20:43:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300854, encodeId=434e300854aa, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Thu Mar 29 11:53:13 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361138, encodeId=6edb13611385b, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535919, encodeId=0c401535919d4, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604175, encodeId=955816041e54e, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300247, encodeId=270a30024e85, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Mar 27 19:58:13 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046948, encodeId=969920469488d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 21 18:43:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004693, encodeId=2ee0200469350, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Mon Oct 15 20:43:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300854, encodeId=434e300854aa, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Thu Mar 29 11:53:13 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361138, encodeId=6edb13611385b, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535919, encodeId=0c401535919d4, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604175, encodeId=955816041e54e, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300247, encodeId=270a30024e85, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Mar 27 19:58:13 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046948, encodeId=969920469488d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 21 18:43:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004693, encodeId=2ee0200469350, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Mon Oct 15 20:43:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300854, encodeId=434e300854aa, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Thu Mar 29 11:53:13 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361138, encodeId=6edb13611385b, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535919, encodeId=0c401535919d4, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604175, encodeId=955816041e54e, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300247, encodeId=270a30024e85, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Mar 27 19:58:13 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
    2018-03-29 刘煜

    阅读

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2046948, encodeId=969920469488d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 21 18:43:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004693, encodeId=2ee0200469350, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Mon Oct 15 20:43:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300854, encodeId=434e300854aa, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Thu Mar 29 11:53:13 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361138, encodeId=6edb13611385b, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535919, encodeId=0c401535919d4, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604175, encodeId=955816041e54e, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300247, encodeId=270a30024e85, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Mar 27 19:58:13 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
    2018-03-29 liuhuangbo
  5. [GetPortalCommentsPageByObjectIdResponse(id=2046948, encodeId=969920469488d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 21 18:43:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004693, encodeId=2ee0200469350, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Mon Oct 15 20:43:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300854, encodeId=434e300854aa, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Thu Mar 29 11:53:13 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361138, encodeId=6edb13611385b, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535919, encodeId=0c401535919d4, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604175, encodeId=955816041e54e, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300247, encodeId=270a30024e85, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Mar 27 19:58:13 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2046948, encodeId=969920469488d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 21 18:43:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004693, encodeId=2ee0200469350, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Mon Oct 15 20:43:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300854, encodeId=434e300854aa, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Thu Mar 29 11:53:13 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361138, encodeId=6edb13611385b, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535919, encodeId=0c401535919d4, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604175, encodeId=955816041e54e, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300247, encodeId=270a30024e85, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Mar 27 19:58:13 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2046948, encodeId=969920469488d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 21 18:43:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004693, encodeId=2ee0200469350, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Mon Oct 15 20:43:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300854, encodeId=434e300854aa, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Thu Mar 29 11:53:13 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361138, encodeId=6edb13611385b, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535919, encodeId=0c401535919d4, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604175, encodeId=955816041e54e, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Mar 29 10:43:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300247, encodeId=270a30024e85, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Mar 27 19:58:13 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
    2018-03-27 1e0f8808m18(暂无匿称)

    好文章.学习了.

    0

相关资讯

Ann Allergy Asthma Immunol:过敏性鼻炎病人的嗜碱性粒细胞表现出了胸腺基质淋巴生成素受体的过敏原特异性上调

过敏性鼻炎(AR)的诊断主要基于典型的鼻症状和过敏原敏化测试。然而,有时候在区分AR和非AR患者时具有难度,并且鉴定AR患者的起因性过敏原从而进行针对性的免疫治疗尤其困难。最近,有研究人员鉴定了AR病人之间的差异,使得受试者具有无症状的敏化作用(AS)和受试者没有过敏(NS)能够进行AR的诊断。研究发现,细胞因子受体因子2和它的产物-胸腺基质淋巴生成素受体(TSLPR)在过敏原刺激后的AR患者中的

Immunotherapy:单磷酰脂质A辅助的特异性免疫治疗在患有花粉过敏患者中的长期影响研究

单磷酰脂质A辅助的超短疗程花粉免疫治疗(MPL)与传统的过敏原特异性免疫治疗(AIT)相比是具有吸引力的。然而,MPL-AIT的长期治疗效果还没有进行评估。最近,有研究人员在对花粉过敏的68名过敏性鼻炎患者中(年龄16.75 ±5.3岁 )进行了调查。研究包括了3个小组,组1为21名对照,组2为19名完成AIT的病人,组3为28名具有AIT治疗和治疗终止的病人。研究发现,与没有AIT治疗的对照相比

Ther Clin Risk Manag:城市过敏性鼻炎儿童的变化的气源性致敏原谱回顾性研究

最近,有研究人员调查了过去10年的中国广州患有过敏性鼻炎(AR)儿童中,气源性过敏原谱和趋势的变化情况。研究是一个回顾性的研究,包括了4111名鼻高反应的儿童。研究人员对他们进行了血清特异性免疫球蛋白E测量,并在3328名患者中检测到了阳性结果,即为AR。另外,研究人员还对不同气源性致敏的阳性率和趋势进行了评估。研究发现,在AR儿童中,常见的气源性过敏原屋尘螨(HDMs)、猫狗皮屑、蟑螂、霉菌混合

Int Arch Allergy Immunol:成年人过敏性鼻炎中,白藜芦醇初级临床效果评估

白藜芦醇是一种天然的、非黄酮类多酚物质,具有抗炎症活性。之前有报道指出,白藜芦醇与羧甲基-β-葡聚糖一起使用能够在儿童过敏性鼻炎(AR)中减少鼻部症状。最近,有研究人员调查了白藜芦醇在患有AR的成年人中的治疗效果。研究人员进行了一个安慰剂对照、双盲研究。研究包括了151名(年龄18-60岁)患有重度永久性AR的成年人,并将他们分成安慰剂处理组(n=50)和布地奈德处理组(n=50)以及一个白藜芦醇

J Laryngol Otol:永久性过敏性鼻炎儿童标准化特异性舌下免疫治疗长期效果分析

最近,有研究人员观察和分析了永久过敏性鼻炎儿童中,单敏和多敏儿童对屋尘螨过敏的标准化特异性舌下免疫治疗5年时间的治疗效果。研究时间为2007年到2009年,包括了236名永久过敏性鼻炎的儿童,并且被分为2组:组1利用屋尘螨提取物进行了标准化的特异性舌下免疫治疗;另1个小组利用鼻用糖皮质激素和口腔抗组胺药物进行了药物治疗。研究总共包括了193名病人(106在免疫治疗小组和87名在药物治疗小组)完成了

Allergy:过敏性鼻炎患者舌下免疫治疗后,Th2细胞特异性减少

尽管Th2细胞在过敏性疾病,如过敏性鼻炎(AR)中具有很重要的角色,但是能够诱导和维持AR发病机理的因素仍旧不清楚。最近的舌下免疫治疗(SLIT)的发展有希望能够对AR的发病机理进行阐释。然而,哪一类Th2细胞亚群在屋尘螨诱导的AR(HDM-AR)中具有重要作用,SLIT对Th2细胞病理学影响以及Th2细胞亚群与SLIT效果之间的联系还没有明确的解释。最近,有研究人员在89名HDM-AR病人(43